DFO indicates deferoxamine; DFX, deferasirox; DFP, deferiprone.

See Table 1 and text for dose ranges. Address adherence concerns and discuss strategies to improve adherence. If escalation is required and patient is receiving maximal dose or cannot tolerate due to toxicity, consider switching agent or combination therapy.

†Close monitoring for adverse events with dose adjustments as needed; use lower doses for growing children to avoid bone and other toxicity.

‡Due to lack of data, the use of deferasirox in patients with low cardiac T2* and cardiac dysfunction is not recommended routinely.